All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel 
.
| Security |
Imputed
Share Price |
Prev
Shares |
Current
Shares |
Change
(Percent) |
Prev Value
(USD x1000) |
Current Value
(USD x1000) |
Change
(Percent) |
|---|
| US33830X1046 / Five Prime Therapeutics Inc
|
|
|
|
|
|
|
|
| RLMD / Relmada Therapeutics, Inc.
|
|
|
|
|
|
|
|
| LSAQ / LifeSci Acquisition II Corp
|
|
|
|
|
|
|
|
| PMVP / PMV Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| KRON / Kronos Bio, Inc.
|
|
|
|
|
|
|
|
| EPIX / ESSA Pharma Inc.
|
|
|
|
|
|
|
|
| ISEE / IVERIC bio Inc
|
|
|
|
|
|
|
|
| SBTX / Silverback Therapeutics Inc
|
|
|
|
|
|
|
|
| TPST / Tempest Therapeutics, Inc.
|
|
|
|
|
|
|
|
| IMVT / Immunovant, Inc.
|
|
|
|
|
|
|
|
| DYNE / Dyntek Inc
|
|
|
|
|
|
|
|
| US2103731061 / Constellation Pharmaceuticals Inc
|
|
|
|
|
|
|
|
| IVA / Inventiva S.A. - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| XENE / Xenon Pharmaceuticals Inc.
|
|
|
|
|
|
|
|
| CLDX / Celldex Therapeutics, Inc.
|
|
|
|
|
|
|
|
| SURF / Surface Oncology Inc
|
|
|
|
|
|
|
|
| MREO / Mereo BioPharma Group plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| MCRB / Seres Therapeutics, Inc.
|
|
|
|
|
|
|
|
| SNDX / Syndax Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| CYCC / Cyclacel Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| CCCC / C4 Therapeutics, Inc.
|
|
|
|
|
|
|
|
| MRSN / Mersana Therapeutics, Inc.
|
|
|
|
|
|
|
|
| MGNX / MacroGenics, Inc.
|
|
|
|
|
|
|
|
| CBAY / CymaBay Therapeutics, Inc.
|
|
|
|
|
|
|
|
| ACRS / Aclaris Therapeutics, Inc.
|
|
|
|
|
|
|
|
| GNCA / Genocea Biosciences Inc
|
|
|
|
|
|
|
|
| BLSA / BCLS Acquisition Corp - Class A
|
|
|
|
|
|
|
|
| KALV / KalVista Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| TRIL / Trillium Therapeutics Inc
|
|
|
|
|
|
|
|
| STSA / Satsuma Pharmaceuticals Inc
|
|
|
|
|
|
|
|
| VTGN / Vistagen Therapeutics, Inc.
|
|
|
|
|
|
|
|
| COGT / Cogent Biosciences, Inc.
|
|
|
|
|
|
|
|
| VRDN / Viridian Therapeutics, Inc.
|
|
|
|
|
|
|
|
| PTGX / Protagonist Therapeutics, Inc.
|
|
|
|
|
|
|
|
| KURA / Kura Oncology, Inc.
|
|
|
|
|
|
|
|
